Navigation Links
International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease

Results presented at the Movement Disorder Society's 11th International Congress in Istanbul, Turkey

KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- New information on the use of AZILECT(R) (rasagiline tablets) for the treatment of Parkinson's disease (PD) was reported this week at The Movement Disorder Society's congress in Istanbul, Turkey. Once-daily AZILECT was approved by the FDA May 17, 2006, for the treatment of the signs and symptoms of PD, both as initial monotherapy and as adjunct therapy to levodopa.

AZILECT(R) Monotherapy Demonstrates Benefits in Early PD Regardless of Disease Duration

Dr. John Bertoni, M.D., Ph.D., provided the results of a new post-hoc analysis of the 26-week, multicenter, randomized, double-blind TEMPO study, that included 404 patients who received once-daily AZILECT 1mg, 2mg, or placebo. This analysis revealed that AZILECT once-daily as monotherapy provided a consistent beneficial effect on the symptoms of PD regardless of the duration of the disease at the time treatment was started. AZILECT 1 mg/day significantly improved UPDRS-Total score compared to placebo in both the < 1-year stratum (-0.52 vs 3.33; p<0.001) and the greater than or equal to 1-year stratum (0.81 vs 4.76; p<0.01). "The time to diagnosis and initial treatment is different for every patient," said Dr. Bertoni. "Demonstrating that AZILECT monotherapy has a beneficial effect, regardless of disease duration, is important when considering it as a treatment option for patients with PD."

AZILECT(R) Clinical Experience When Given Concomitantly with Antidepressants

Dr. Michel Panisset, M.D., CHUM - Hotel-Dieu de Montreal, Quebec, reported on an evaluation of the records of 1,361 patients who had taken AZILECT for the treatment of Parkinson's disease in controlled clinical trials to assess the safety of combining antidepressant therapy with AZILECT. Three hundred and twenty three ( 323) of the total 1,361 patients (24%) were noted to have taken a concomitant antidepressant, including amitriptyline, sertraline, paroxetine, trazodone, and citalopram. No apparent cases of serotonin toxicity (ST) occurred. Symptoms that occurred more frequently with the combination of AZILECT plus antidepressant could be accounted for as being symptoms of either antidepressant use or of depression.

"Rates of termination of treatment were similar, with and without antidepressants, further supporting the relative safety of AZILECT(R) (rasagiline tablets) combined with antidepressants," said Dr. Panisset. "Twenty four percent of the total number of AZILECT treated PD patients were also taking antidepressants. Seeing this apparent lack of serotonin toxicity is important."

According to the US prescribing information the exposure during development, both in dose and number of subjects was not adequate to rule out the possibility of an untoward reaction from combining AZILECT with antidepressants. Other MAO-B inhibitors are labeled similarly.


AZILECT is indicated for the treatment of the signs and symptoms of Parkinson's disease (PD) both as initial therapy alone and to be added to levodopa later in the disease. The effectiveness of AZILECT was shown in patients with early PD who were receiving AZILECT as initial therapy alone and who were not receiving any other PD therapy. The effectiveness of AZILECT as adjunct therapy was shown in patients with PD who were treated with levodopa.

    -- You should not take AZILECT if you are currently taking meperidine as

       it could possibly result in a serious reaction such as coma or death.

    -- You should not take AZILECT with tramadol, methadone, propoxyphene,

       dextromethorphan, St. John's wort, mirtazapine, or cyclobenzaprine.

    -- You should not take AZILECT with other monoamine oxidase inhibitors

       (MAOIs), amphetamines, cold remedies containing dec
ongestants and

       weight-reducing preparations containing pseudoephedrine, phenylephrine,

       phenylpropanolamine, or ephedrine in order to avoid a possibly

       dangerous increase in blood pressure. Symptoms of this reaction include

       severe headache, blurred vision, difficulty thinking, seizures, chest

       pain, unexplained nausea or vomiting, or signs or symptoms of a stroke.

       You or your caregiver should seek immediate medical attention if these

       symptoms or other unusual symptoms occur.

    -- In order to prevent a possibly dangerous increase in blood pressure,

       when taking AZILECT you should avoid foods and beverages high in

       tyramine content such as aged cheeses, air-dried meats, pickled

       herring, yeast extract, aged red wines, tap/draft beers, sauerkraut,

       and soy sauce.

    -- When taking AZILECT, you should not have elective surgery requiring

       general anesthesia, and should not receive cocaine or other local

       anesthesia that contains ingredients that could raise blood pressure.

    -- You should inform your physician if you are taking, or planning to

       take, any prescription or over-the-counter drugs, especially

       antidepressants and ciprofloxacin.

    -- If you have moderate to severe liver disease or a tumor of the adrenal

       gland, you should not take AZILECT.

    -- All PD patients are advised to monitor for melanoma (skin cancer)

       frequently and see a dermatologist on a regular basis.

Side effects seen with AZILECT alone are headache, joint pain and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesias), accidental injury, nausea, weight loss, constipation, low blood pressure when standing, joint pain, vomiting, dry mouth, rash, and sleepiness. Be sure to tell your doctor about these and any other side effects you experience when taking AZILECT.

About Parkinson's Disease

Parkinson's disease is an age-related degenerative disorder of the brain. Symptoms can include tremor, stiffness, slowness of movement, and impaired balance. An estimated 1 million Americans have the disease, which usually affects people over the age of 60.

About Teva

Teva Pharmaceutical Industries Ltd. , headquartered in Israel, is among the top 20 pharmaceutical companies in the world. The company develops, manufactures, and markets innovative and generic human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

Teva's U.S. innovative product marketing subsidiary, Teva Neuroscience, Inc., promotes AZILECT in the United States. AZILECT is a registered trademark of Teva Pharmaceutical Industries Ltd.

Please visit for additional important information.

Please see enclosed additional important information.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may pre vent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra(R) and Neurontin(R), the effects of competition on our innovative products, especially Copaxone(R) sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


C ONTACT: Warren Dudley, +1-816-512-2381, , or LizDunavant, +1-816-512-2246, , both ofFleishman-Hillard Inc. for Teva Neuroscience, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:TEVA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
Breaking Medicine Technology:
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
Breaking Medicine News(10 mins):